2022
Advances in antibody-drug conjugates for gynecologic malignancies
Tymon-Rosario J, Gorman M, Richardson D, Washington C, Santin A. Advances in antibody-drug conjugates for gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2022, 35: 6-14. PMID: 36484278, DOI: 10.1097/gco.0000000000000838.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesOvarian cancer patientsGynecologic malignanciesCancer patientsPlatinum-resistant ovarian cancer patientsUse of ADCsOngoing phase 3 trialsRecurrent ovarian cancer patientsNovel antibody-drug conjugateReceptor-targeting antibodiesPhase 3 trialProgression-free survivalFirst U.S. FoodOngoing clinical trialsHER2/neuPersonalized cancer careTisotumab vedotinPrimary endpointCervical cancerGynecologic cancerCancer careClinical trialsMultiple tumorsCurrent evidenceDrug Administration
2007
Local Administration of Interleukin-11 Ameliorates Intestinal Radiation Injury in Rats
Boerma M, Wang J, Burnett AF, Santin AD, Roman JJ, Hauer-Jensen M. Local Administration of Interleukin-11 Ameliorates Intestinal Radiation Injury in Rats. Cancer Research 2007, 67: 9501-9506. PMID: 17909060, DOI: 10.1158/0008-5472.can-07-0810.Peer-Reviewed Original ResearchConceptsIntestinal radiation injuryRadiation injuryRhIL-11Bowel loopsMucosal mast cell numbersIL-11Whole body radiation exposureRecombinant human IL-11Small bowel loopsED2-positive cellsRadiation injury scoreIntestinal wall thickeningMast cell numbersIntestinal radiation responseLocal administrationHuman IL-11Pelvic radiotherapySurgical transpositionIntraluminal administrationInjury scoreIntestinal loopsMale ratsSystemic administrationSevere toxicityDrug Administration